Tank exciting joining you, Derrick and XXXX for Biomedicine year was for Group. today. us Cellular thank you everyone an
footprint expanding are in We Maryland. our
are We the the foot QX. clinical Rockville. in to U.S. expansion is to move to research facility expand in capabilities development a square our We This further support and the in new development XX,XXX facility into plan renovating and late
achieved immuno-oncology, we the On or IO four milestones. major side,
a efficacy infusion. clinical early refractory post showed All initiated Hematology, We showed the First, at of or China. five in for data clinical myeloma December. multiple weeks as CAR American improvement safety two data of patients. relapsed our of patient for in and recruitment presented T ASH, we study on a as Annual five therapy anti-BCMA or Society We Conference initial
more we optimistic it dosing from low The encouraging, would The data. be and at needs preclinical the findings accumulate sub-optimal very index therapeutic research our drug early after clinical early to signal are we confirmed. results efficacy cautiously and show meaningful is that support but
will and of be available. as due at and patients evaluate monitor duration data although to the continue continue coronavirus will enroll to it we response to rate we’ll a becomes the will We more it the slower evaluate and
started CDXX anti-CDXX non-Hodgkins NHL development consider U.S., Based clinical we BiCar on signal, Secondly, of in there Lymphoma evaluate may we if the or China. in the is clinical have edge. relapsed-refractory believe patients we clear a assay R/R competitive to
cancer alpha-fetoprotein Thirdly, AFP-TCR-T Receptor with in our X.X HCC China year. almost patient T has liver we or dosed patients first China. million of cell each new
our CAR-T or CAR-T-treated previously study we B-Cell Finally, Anti-CDXX lymphoma China. DLBCL patients targeting in for anti-CDXX initiated diffuse large relapsed
launch after and investigator collaboration start to asset, good infiltrating IND our or TIL treatment obtain IO non-small migrate are refractory center. the our to toward that a XXXX tumor proof of medical partner Regarding planning provide IO in or us we’re Indeed, cell with the leading pipeline lymphocytes in relapsed cancer to try U.S. on lung study patients principal concept filings.
candidates, We’re in our advance the U.S. and continuing to China drug both
for pipeline, on QX our adipose-derived knee in as a to advance in this osteoarthritis X KOA human the we launched cell trial Phase mesenchymal therapy or Phase KOA medicine X trial our plan regenerative off-the-shelf China potential multicenter year. Regarding we or multicenter and progenitor haMPC autologous allogeneic
up $XX $XX.X $XX.X compared with XXXX. and million cash, million a balance we cash, million cash month, restricted in secured loan our year last bridge the ended equivalent with And show sheet. We for to
for short-term to and debt $XX.X none XXXX. compared have million in We
development. for with research $XX.X million and year-over-year operating net cash increase was for to Our million used XXXX. in The $XX.X activities compared
The already in still has situation as of you’re there since good. disease spread Wuhan, and impacted COVID-XX. As an or global coronavirus is ongoing been rapidly. aware, last has outbreak has began year December of It China CBMG
slowdown system all recruitment extent impact predicted. our adjusted the will clinical in which for had is We the recruitment to the hospital quickly business, negatively patient operations COVID-XX. be of deal and the to coronavirus anticipate of studies The in in China have a highly patients has full study. our slowdown accurately uncertain challenges for as cannot We with a our and surrounded results
to supporting provide clinical recently We’re mesenchymal severe caused in the in which exosomes committed cell and stem communities Ruijin Shanghai operate novel Hospital coronavirus we pneumonia with trial. collaborated treat to have human their to
and Group Biomedicine the progress – clinical our continued business. Cellular Overall side operating both to on of operational has
our and vision start-ups manufacturing cell of capable execute and We’re embraced with capabilities provided platform bring continuing by benefits has global therapies as to been therapies research innovative development, a cancer. to globally. Cell large intends benefit therapy biopharma to to pharmas and to to cure both build integrated vein-to-vein CBMG help clinical namely to capabilities clear and patients external the collaborations internal patients robust well leverage our as patients.
for that, discussion our turn With will back have I questions Derrick, for you any opening us. may to you
